In Group 4 (IDH-WT AA), we found that patients with TERTp-mutant tumor showed shorter median survival compared to patients with TERTp-WT tumors [median survival with 95% CI: 8.0 months (0.000–20.002) vs. 18.1 months (0.000–46.107), respectively]; however, TERTp mutation status did not have an statistically significant effect on OS or PFS (Table 5, Fig. 5c and d), possibly because the number of TERTp mutant cases were too few to attain statistical significance (P = 0.113). The gene discussed is IDH1; the disease is neoplasm.